Literature DB >> 533413

Long-term experience with the technique of subclavian and femoral vein cannulation in hemodialysis.

J Erben, J Kvasnicka, J Bastecký, J Groh, J Zahradník, V Rozsíval, D Bastecká, P Fixa, J Kozák, V Herout.   

Abstract

Large vein cannulation for hemodialysis was used in 1164 patients undergoing dialysis treatment and in an acute dialysis program. Subclavian vein cannulation was utilized in 2494 dialyses, and femoral vein cannulation was used in 2368 dialyses. No significant differences with regard to clinical complications were encountered in either type of cannulation. The mortality rate due to subclavian vein cannulation was 0.12%, while that due to femoral vein cannulation was 0.04%. The main risk of subclavian vein cannulation was arterial bleeding, due to trauma to an artery, and pneumothorax, more likely occurring in asthenic patients or in patients with emphysema. Single-needle hemodialysis using subclavian or femoral vein cannulation gave the same results as the arteriovenous Cimino fistula. Intermittent or combined use of both types of large vein cannulation is advantageous in long-term regular dialysis patients that are waiting for a new fistula.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533413     DOI: 10.1111/j.1525-1594.1979.tb01056.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  3 in total

1.  Femoral arteriovenous fistula: a complication of temporary hemodialysis catheter placement.

Authors:  Gen Kuramochi; Nobumasa Ohara; Shin Hasegawa; Hisanaga Moro
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

2.  Learning from mistakes: femoral vein cannulation-an unusual complication or a blessing in disguise!!!

Authors:  Ajay Malviya; J K Yadav; Nitin Negi; C Gautam Singh
Journal:  Indian J Surg       Date:  2011-06-04       Impact factor: 0.656

3.  Percutaneous catheterization of the internal jugular vein for hemodialysis.

Authors:  C H Yeum; S W Kim; M Y Nah; S K Ma; J H Ko; N H Kim; K C Choi
Journal:  Korean J Intern Med       Date:  2001-12       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.